Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis

Detalles Bibliográficos
Autores principales: Suzuki, K, Sunami, K, Ohashi, K, Iida, S, Mori, T, Handa, H, Matsue, K, Miyoshi, M, Bleickardt, E, Matsumoto, M, Taniwaki, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380903/
https://www.ncbi.nlm.nih.gov/pubmed/28282035
http://dx.doi.org/10.1038/bcj.2017.18
_version_ 1782519833740443648
author Suzuki, K
Sunami, K
Ohashi, K
Iida, S
Mori, T
Handa, H
Matsue, K
Miyoshi, M
Bleickardt, E
Matsumoto, M
Taniwaki, M
author_facet Suzuki, K
Sunami, K
Ohashi, K
Iida, S
Mori, T
Handa, H
Matsue, K
Miyoshi, M
Bleickardt, E
Matsumoto, M
Taniwaki, M
author_sort Suzuki, K
collection PubMed
description
format Online
Article
Text
id pubmed-5380903
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53809032017-05-01 Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis Suzuki, K Sunami, K Ohashi, K Iida, S Mori, T Handa, H Matsue, K Miyoshi, M Bleickardt, E Matsumoto, M Taniwaki, M Blood Cancer J Letter to the Editor Nature Publishing Group 2017-03 2017-03-10 /pmc/articles/PMC5380903/ /pubmed/28282035 http://dx.doi.org/10.1038/bcj.2017.18 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Letter to the Editor
Suzuki, K
Sunami, K
Ohashi, K
Iida, S
Mori, T
Handa, H
Matsue, K
Miyoshi, M
Bleickardt, E
Matsumoto, M
Taniwaki, M
Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
title Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
title_full Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
title_fullStr Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
title_full_unstemmed Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
title_short Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
title_sort randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: eloquent-2 japanese patient subanalysis
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380903/
https://www.ncbi.nlm.nih.gov/pubmed/28282035
http://dx.doi.org/10.1038/bcj.2017.18
work_keys_str_mv AT suzukik randomizedphase3studyofelotuzumabforrelapsedorrefractorymultiplemyelomaeloquent2japanesepatientsubanalysis
AT sunamik randomizedphase3studyofelotuzumabforrelapsedorrefractorymultiplemyelomaeloquent2japanesepatientsubanalysis
AT ohashik randomizedphase3studyofelotuzumabforrelapsedorrefractorymultiplemyelomaeloquent2japanesepatientsubanalysis
AT iidas randomizedphase3studyofelotuzumabforrelapsedorrefractorymultiplemyelomaeloquent2japanesepatientsubanalysis
AT morit randomizedphase3studyofelotuzumabforrelapsedorrefractorymultiplemyelomaeloquent2japanesepatientsubanalysis
AT handah randomizedphase3studyofelotuzumabforrelapsedorrefractorymultiplemyelomaeloquent2japanesepatientsubanalysis
AT matsuek randomizedphase3studyofelotuzumabforrelapsedorrefractorymultiplemyelomaeloquent2japanesepatientsubanalysis
AT miyoshim randomizedphase3studyofelotuzumabforrelapsedorrefractorymultiplemyelomaeloquent2japanesepatientsubanalysis
AT bleickardte randomizedphase3studyofelotuzumabforrelapsedorrefractorymultiplemyelomaeloquent2japanesepatientsubanalysis
AT matsumotom randomizedphase3studyofelotuzumabforrelapsedorrefractorymultiplemyelomaeloquent2japanesepatientsubanalysis
AT taniwakim randomizedphase3studyofelotuzumabforrelapsedorrefractorymultiplemyelomaeloquent2japanesepatientsubanalysis

Ejemplares similares